Even worse for the market leaders, many companies in India and China already produce conventional insulins at much lower costs to patients -- some as low as $3/vial. Unless the current insulin leaders can cut their conventional insulin manufacturing costs to compete with these up-and-comers, they could potentially see themselves cut out of the insulin market altogether. Cutting Edge Information's "Diabetes Market Forecast to 2013" (http://cuttingedgeinfo.com/Diabetes/index.htm) examines trends affecting the diabetes space today and their impact leading into the next decade. It details the historical, current and forecasted performance of more than 50 drugs -- including marketed brands and those still in development -- as well as the top seven drug makers in the diabetes market. Brand profiles include the following information:
-- Drug's current and projected competitive strength -- Current/projected sales position within drug class -- Sales projection charts for the next four to seven years -- Competitive assessment -- Clinical trial informationThe manufacturer profiles contain:
-- Company ranking in diabetes market -- Strengths analysis -- Growth areas analysis -- Competition analysis -- Key products breakdownLearn more about the report and download a brochure at http://cuttingedgeinfo.com/Diabetes/index.htm
Contact Information: For questions or comments, please contact: Jeremy Spivey 919-433-0373